title: FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.
abstract: FGFR1 amplification has been identified recently as an important therapeutic target in non-small-cell lung cancer (NSCLC), particularly squamous cell carcinoma (SqCC). However, data from previous studies on the clinical implications of FGFR amplification in NSCLC are inconsistent. We evaluated FGFR1 gene copy number (GCN) in 369 cases of surgically resected NSCLC using five previously reported criteria and investigated associations between clinicopathologic parameters and FGFR1 amplification. FGFR1 amplification was found in 32/369 (8.7 %) of NSCLC and was more frequent in SqCC (18.0 % in SqCC, 3.0 % in adenocarcinoma; p < 0.001) and in smokers (p < 0.001). On univariate analysis, FGFR1 amplification was significantly associated with shorter overall survival (OS, 58.6 vs 80.0 months; p = 0.033) and shorter disease-free survival (DFS, 58.5 vs 80.0 months; p = 0.042) in patients with SqCC, but this was not statistically significant on multivariate analysis (OS: hazard ratio [HR] = 1.79, 95 % confidence interval [CI] = 0.83-3.87, p = 0.139; DFS: HR = 1.73, 95 % CI = 0.93-3.21, p = 0.081). The correlation between FGFR1 amplification and protein expression was poor (rho = 0.08; p = 0.123). These results suggest that FGFR1 amplification is associated with smoking history and squamous cell carcinoma histology and might indicate poor prognosis.
authors.affiliation: Department of Pathology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Jung-gu, Daegu, Republic of Korea.
authors.forename: An Na
authors.initials: AN
authors.lastname: Seo
authors.forename: Yan
authors.initials: Y
authors.lastname: Jin
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Lee
authors.forename: Ping-Li
authors.initials: PL
authors.lastname: Sun
authors.forename: Hyojin
authors.initials: H
authors.lastname: Kim
authors.forename: Sanghoon
authors.initials: S
authors.lastname: Jheon
authors.forename: Kwhanmien
authors.initials: K
authors.lastname: Kim
authors.forename: Choon-Taek
authors.initials: CT
authors.lastname: Lee
authors.forename: Jin-Haeng
authors.initials: JH
authors.lastname: Chung
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005784:Gene Amplification; D018628:Gene Dosage; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000096:biosynthesis / Q000235:genetics*; D012189:Retrospective Studies; D012907:Smoking
chemical_list: D051496:Receptor, Fibroblast Growth Factor, Type 1
references.citation: Lung Cancer. 2013 Sep;81(3):462-467
references.pmid: 23806793
references.citation: Virchows Arch. 2012 Jul;461(1):49-57
references.pmid: 22648708
references.citation: J Thorac Oncol. 2010 Jul;5(7):964-9
references.pmid: 20512074
references.citation: Curr Cancer Drug Targets. 2012 Feb;12(2):107-23
references.pmid: 22165970
references.citation: J Exp Clin Cancer Res. 2012 Dec 27;31:103
references.pmid: 23270564
references.citation: Biochem Biophys Res Commun. 2002 Aug 9;296(1):152-5
references.pmid: 12147242
references.citation: Mod Pathol. 2002 Dec;15(12):1374-80
references.pmid: 12481020
references.citation: Breast Cancer Res. 2012 Aug 03;14(4):R115
references.pmid: 22863309
references.citation: Sci Transl Med. 2013 Oct 30;5(209):209ra153
references.pmid: 24174329
references.citation: PLoS One. 2011;6(6):e20351
references.pmid: 21666749
references.citation: Mod Pathol. 2011 Oct;24(10):1327-35
references.pmid: 21666686
references.citation: Mol Cancer Ther. 2012 Mar;11(3):690-9
references.pmid: 22238366
references.citation: Sci Transl Med. 2010 Dec 15;2(62):62ra93
references.pmid: 21160078
references.citation: Semin Radiat Oncol. 2008 Apr;18(2):89-97
references.pmid: 18314063
references.citation: Int J Cancer. 2013 Aug 15;133(4):898-907
references.pmid: 23400671
references.citation: Neoplasma. 1997;44(5):295-8
references.pmid: 9473788
references.citation: Lung Cancer. 2013 Jun;80(3):249-55
references.pmid: 23489560
references.citation: Mod Pathol. 2012 Nov;25(11):1473-80
references.pmid: 22684217
references.citation: Cancer Res. 2013 Jun 15;73(12):3716-24
references.pmid: 23576558
references.citation: Sci Transl Med. 2010 Dec 15;2(62):62ps56
references.pmid: 21160076
references.citation: Mol Med Rep. 2012 Mar;5(3):725-8
references.pmid: 22179561
references.citation: Korean J Pathol. 2013 Feb;47(1):44-51
references.pmid: 23483484
references.citation: Genes Chromosomes Cancer. 2007 Nov;46(11):1028-38
references.pmid: 17696196
references.citation: Oral Oncol. 2013 Jun;49(6):576-81
references.pmid: 23434054
references.citation: Oncol Rep. 2007 Mar;17(3):557-64
references.pmid: 17273733
references.citation: J Clin Oncol. 2013 Feb 20;31(6):731-7
references.pmid: 23182986
references.citation: J Thorac Oncol. 2012 Dec;7(12):1775-1780
references.pmid: 23154548
references.citation: J Thorac Oncol. 2011 Feb;6(2):244-85
references.pmid: 21252716
references.citation: Clin Cancer Res. 2012 Dec 15;18(24):6658-67
references.pmid: 23082000